Member Info for LTbeliever

Being devil's advocate here, didn't the CEO invest 50k of his own money into the Nov. placing? It was 7 months ago, and a lot was counting on the $2.5mln Haleon payment by June 2026 (at the time); is it unreasonable for them to have factored in their CF projections either a delay in the US Patent grant and/or the Haleon pmnt? In addition, when they asked for the money in November, they probably assured the Placees that they'd take steps to ensure that no Placing would be needed in 2026; IMO it's quite likely that they will avoid a Placing, as they should still have cash until Q3 end, or longer (depending on sales of products and/or assets).

This time it's different IMO; Daemeneng has been burning its own cash since last October, to set things for launch; they burned more cash during the above-average rainy season, to rectify the flooded operations; hence, they have a huge incentive to start getting some payback. 1-2 weeks and we'll know.

Hi all, new here; is it far fetched to consider that they may get by for another few weeks to eg Q3 end? Co had 3.4mln at Y/E 2025 and 2.4mln at Q1 2026 end (30 March) as per the RNS dated 29 Apr., so was burning appx 330k of cash monthly; last year it had some Sales, now, 6 month into 2026 if they have had sales of eg 1.5mln @60% margin, that's almost another 3 months of cash flow; so, by June end, cash b/ce could be +2mln?

Magpie, no offence taken; as people skim through posts, I tried to keep it short; I was referring to one of the connections (see link below), which referred to the "treatment of fibrosis", not IPF per se. Apologies for using "fix" in lieu of "treat. I will try to be more accurate next time.

https://www.deepscienceventures.com/articles/deep-science-ventures-and-general-inception-collaborate-to-create-fibrosis-focused-therapeutics-company

What matters is, IMO, if and how this piece of info will/may affect the SP; in the short run, possibly a small jolt (as the info was already - indirectly - in the public domain and insiders were/are aware if any collaboration will happen); in the medium term, if there will be a true collaboration, then the SP will benefit tremendously; they are not aiming to fix just IPF but all fibrosis-related conditions (1 in 5 people die from such conditions as it includes cirrhosis, for example); time will tell, GLA, we are all in it together.

All good news wrapped in one RNS then, looking fwd to it :)

You mean H1 update maybe? There are no quarterly updates but if near period end (H1 2026), we may get some news especially if there have been positive developments; though in the past, nothing was released around the AGM time; in any case, we'd get an update about the CEO's bonus; ideally, payable in cash by Y/E (less dilution) as it'd be a positive signal to the market that the Co is making money and has cash to pay it - just IMO.

This time I have a feeling that we ll all be pleasantly surprised; Placing out of the way, US markets coming down to earth (meaning more capital available for RoW and other sectors), Co gearing up for production/gradual expansion. Not long left for the update IMO, GLA.

I think they prefer to issue op updates with info on various fronts; so, not having one so far doesn't mean they are not already selling DMS; IMO, we'll get an update around mid-June.

Need to remember that these technologies were developed over many years by Microsaic (spectrometer) and ModernWater (toxicity detectors) after many millions had been spent; their problem was that the running expenses always exceeded by revenues; if not mistaken, MWater was bought by DVRG a few years back for a few million in shares; however I was a bit dissappointed by Bob mentioning that SRB kits are still out of production since December.

Looks like some Ptaking is occurring; could be the Placees from last June (@0.65) maybe; I don't think the ones from December (@0.75) would bother. IMO, we'll get another buying opportunity soon.

This is probably what has given the SP a fresh push, IMO; TP mention that the PFAS detector leased to Veralto is possibly priced @100.000!

I cannot post the link here for now. GLA

Still waiting for AFS and PD detector update, plus update on MEast (Qatar pmnt, Aramco SRB kit sales etc).

Veralto has annual sales of USd 5bln in Water Quality Services!! see page 8 of Presentation

https://investors.veralto.com/

https://filecache.investorroom.com/mr5ir_veralto/284/VLTO_1Q26_Earnings_Slide_Presentation.pdf

Looks like we will have both the PFAs detector and the PD detector (Cryptosporidium, as a start) fully functioning in 2027 and MET working with big players in the UK and USA, if not the EU too; and if the semiconductors' PFAS detection takes off, then plenty of money to flow. IMO, DYOR

The last one is new and can be very significant!

· First commercial sale of a PFAS detector unit to Nasdaq-listed Veralto, a US$20 billion market cap global leader in essential water and product quality solutions in the US, demonstrating the capability of Metir's unique technology.

· Assessing commercial development opportunities with ProDecon Services, a leading UK PFAS decontamination specialist, for field testing of Metir's PFAS detection platform.

· Memorandum of Understanding ("MOU") signed with FIDCHEM, an innovative European developer of water treatment technologies targeting PFAS and other environmental contaminants, to co-develop AI machine learning functionality designed to simplify data output and interpretation.

· Agreement with Swansea University to transfer full proprietary IP ownership to Metir of the newly developed PFAS field testing method.

· Additional PFAS testing applications under evaluation within the global semiconductor manufacturing sector, supporting exposure to a high-growth, high-value market.

Since the ODD and the Placing, when the Co stated in the RNS that "...Whilst completion of the focused studies will represent important value inflection points for the NXP002 programme it is NOT expected that ALL the studies will need to conclude for an out-licensing or collaborative development transaction to complete."

1. Why did they need to mention this, unless there is a high expectation of it happening? They could have covered themselves by just saying that ALL the studies need completion before any deals can even be considered.

2. There are more than 1 studies, so potentially, more than 1 partners;

3. Due diligence, legal documents etc can take weeks, especially if a big pharma will sign with NFX for a licensing or co-development deal; this means IMO that an RNS can drop any time during the summer.

GLA, DYOR.

Bob had mentioned "several Water cos" so maybe Severn is paying to test the first prototype but others will follow suit; he did mention that they have built several prototypes in anticipation, MET just needs Phase II to be completed; Q2 end was the target for compeltion, so we will see soon if this will be extended into the summer.

Our challenge is with Severn Trent Water. "Ofwat Breakthrough Challenge for Cryptosporidium" as well; deadline is Aug. 2028 so MET could have a head start in early Jan for commercial deployment (see 2nd half of page 3).

https://waterinnovation.challenges.org/wp-content/uploads/sites/3/2026/04/Water-Innovation-Fund-Project-dates-March-2026-5.pdf

USD1.2bln mkt cap, recently raised net $300mln. As said y'day by fellow posters, indicates both the high risks and the high potential rewards if Dan gets it right.

https://investors.avalynpharma.com/static-files/6c72eb80-943d-44ba-b6f7-62e6cef000db

https://investors.avalynpharma.com/news-releases/news-release-details/avalyn-announces-pricing-upsized-initial-public-offering